Alnylam Pharmaceuticals
ALNY
#813
Rank
โ‚ฌ26.79 B
Marketcap
200,24ย โ‚ฌ
Share price
0.05%
Change (1 day)
-48.32%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): โ‚ฌ0.96 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ4.80 Billion. In 2025 the company made an earning of โ‚ฌ0.57 Billion, an increase over its 2024 earnings that were of -โ‚ฌ0.22 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) โ‚ฌ0.96 B66.97%
2025 โ‚ฌ0.57 B-375.96%
2024 -โ‚ฌ0.22 Billion-24.59%
2023 -โ‚ฌ0.28 Billion-67.84%
2022 -โ‚ฌ0.87 Billion36.93%
2021 -โ‚ฌ0.64 Billion-8.04%
2020 -โ‚ฌ0.69 Billion-15.66%
2019 -โ‚ฌ0.82 Billion12.23%
2018 -โ‚ฌ0.73 Billion62.91%
2017 -โ‚ฌ0.45 Billion17.78%
2016 -โ‚ฌ0.38 Billion43.44%
2015 -โ‚ฌ0.27 Billion60.69%
2014 -โ‚ฌ0.17 Billion98.2%
2013 -โ‚ฌ82.89 Million
2011 -โ‚ฌ48.89 Million27.48%
2010 -โ‚ฌ38.35 Million-10.92%
2009 -โ‚ฌ43.05 Million95.77%
2008 -โ‚ฌ22 Million
2006 -โ‚ฌ35.23 Million-9.13%
2005 -โ‚ฌ38.77 Million34.74%
2004 -โ‚ฌ28.78 Million36.79%
2003 -โ‚ฌ21.04 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚ฌ13.84 B 1,280.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚ฌ6.38 B 536.67%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚ฌ4.60 B 359.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚ฌ0.12 Billion-111.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚ฌ42.3 Million-104.22%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚ฌ71.19 Million-107.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ1.43 B 42.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚ฌ0.15 Billion-114.18%๐Ÿ‡บ๐Ÿ‡ธ USA